Contact the Editorial Desk

Correspondence

Ascent Peptides is glad to hear about the research record: a citation rendered inaccurately, a regulatory status that has changed, or a peer-reviewed study on CJC-1295, Sermorelin, or Tesamorelin that should join the references page. Corrections that sharpen the survey are the most useful mail that arrives, and each is read with care.

The notes easiest to act on name three things: the page in question, the exact passage at issue, and the supporting citation — a DOI or PubMed ID wherever possible. That lets a proposed change be checked against its source quickly.

Editorial mailbox: editors@ascentpeptides.com

Outside the survey's remit

A few things sit outside what the site can take on — flagged here so no message waits on an answer it will never get. Ascent Peptides surveys literature; it is not a clinic and not a vendor, so it cannot:

• Advise on, endorse, or comment on human use of any peptide covered here.
• Name a dose, schedule, or route for any individual.
• Diagnose a condition or judge whether a finding fits a particular person.
• Sell, source, recommend, or help you locate any compound from any supplier.
• Field anti-doping questions from athletes about these compounds, all three of which are prohibited in sport.

Anyone seeking medical guidance should consult a licensed clinician in their own jurisdiction. Replies to correspondence are not guaranteed and may lag; the mailbox is checked intermittently.